Michael  Rice net worth and biography

Michael Rice Biography and Net Worth

Michael Rice is the CEO of BioLife Solutions, a leading supplier of class-defining cell and gene therapy bioproduction tools and services. 

Rice joined the company in 2006 as president, CEO and director, and he served as chairman of the board from 2007 to 2013. In his last five years with the company, Rice has driven annual revenue growth to greater than 30 percent. During his tenure, BioLife has twice been named one of Seattle Business Magazine’s 100 Best Companies to Work For.

Prior to BioLife, Rice spent two years as the senior business development manager of medical and wireless products for AMI Semiconductor Inc. His career includes 30 years of experience in leadership and entrepreneurial roles in the medical and high-tech industries, including a four-year stint at Cardiac Science where he worked as the director of business development and marketing. From 1998 to 2000, Rice served as VP of sales and marketing for TEGRIS Corporation, a privately-held network services provider.

Early in his career, Rice held a series of marketing and sales management roles at Physio Control Corporation before it was acquired by Medtronic. He currently serves on the board of Sexton Biotechnologies, and he was formerly a board member for Savsu Technologies from 2014 to 2019. 

Rice earned his B.S. in business administration from City University of Seattle.  

What is Michael Rice's net worth?

The estimated net worth of Michael Rice is at least $9.26 million as of October 30th, 2023. Mr. Rice owns 347,085 shares of BioLife Solutions stock worth more than $9,256,757 as of February 22nd. This net worth estimate does not reflect any other investments that Mr. Rice may own. Learn More about Michael Rice's net worth.

How do I contact Michael Rice?

The corporate mailing address for Mr. Rice and other BioLife Solutions executives is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. BioLife Solutions can also be reached via phone at (425) 402-1400 and via email at rdegreef@biolifesolutions.com. Learn More on Michael Rice's contact information.

Has Michael Rice been buying or selling shares of BioLife Solutions?

Michael Rice has not been actively trading shares of BioLife Solutions within the last three months. Most recently, Michael Rice sold 72,603 shares of the business's stock in a transaction on Monday, October 30th. The shares were sold at an average price of $9.13, for a transaction totalling $662,865.39. Following the completion of the sale, the chief executive officer now directly owns 347,085 shares of the company's stock, valued at $3,168,886.05. Learn More on Michael Rice's trading history.

Who are BioLife Solutions' active insiders?

BioLife Solutions' insider roster includes Sarah Aebersold (VP), Todd Berard (CMO), Roderick de Greef (CFO), Karen Foster (Insider), Andrew Hinson (Director), Aby Mathew (VP), Michael Rice (CEO), Joseph Schick (Director), Marcus Schulz (CRO), and Troy Wichterman (CFO). Learn More on BioLife Solutions' active insiders.

Are insiders buying or selling shares of BioLife Solutions?

In the last twelve months, insiders at the medical equipment provider sold shares 68 times. They sold a total of 179,217 shares worth more than $3,860,661.93. The most recent insider tranaction occured on February, 12th when EVP Aby J Mathew sold 92 shares worth more than $2,441.68. Insiders at BioLife Solutions own 2.2% of the company. Learn More about insider trades at BioLife Solutions.

Information on this page was last updated on 2/12/2025.

Michael Rice Insider Trading History at BioLife Solutions

Michael Rice Buying and Selling Activity at BioLife Solutions

This chart shows Michael Rice's buying and selling at BioLife Solutions by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$2M-$1M$0$1M$2MTotal Insider BuyingTotal Insider Selling

BioLife Solutions Company Overview

BioLife Solutions logo
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Read More

Today's Range

Now: $26.67
Low: $26.42
High: $27.90

50 Day Range

MA: $26.93
Low: $24.98
High: $28.49

2 Week Range

Now: $26.67
Low: $14.50
High: $29.55

Volume

259,865 shs

Average Volume

238,085 shs

Market Capitalization

$1.24 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.91